Core Viewpoint - Berger Montague PC is investigating claims against Fiserv, Inc. following a class action lawsuit alleging that the company overstated its growth by not disclosing issues with its Clover payment platform [1][3]. Group 1: Lawsuit Details - The class action lawsuit claims that Fiserv and certain executives failed to disclose that Clover's revenue growth was artificially inflated due to the forced transition of merchants from the legacy Payeezy platform [3]. - Investors became aware of Fiserv's true financial situation after the company lowered its 2025 organic growth projections on July 23, 2025, leading to a significant decline in share price [4]. Group 2: Investor Information - Investors who purchased Fiserv securities between July 24, 2024, and July 22, 2025, have until September 22, 2025, to seek appointment as lead plaintiff representatives [2][5].

NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in KinderCare Learning Companies, Inc. ("KinderCare Learning Companies, Inc." or the "Company") (NYSE: KLC) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of KinderCare Learning Companies, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of all purchasers of KinderCare common stock in or traceable to the Company’s Octobe ...

Core Viewpoint - Investors in Snap Inc. have the opportunity to lead a securities fraud class action lawsuit due to alleged misleading statements made by the company regarding its advertising growth and earnings potential [1][2]. Summary by Relevant Sections Lawsuit Details - The lawsuit claims that from April 29, 2025, to August 5, 2025, Snap's management failed to disclose critical information, including that their optimistic reports on advertising growth were not reflective of actual performance [2]. - It is alleged that Snap was facing significant execution errors, contradicting the company's claims of a lack of visibility due to macroeconomic conditions [2]. - The positive statements made by Snap's management regarding the company's business and prospects were deemed materially misleading and lacked a reasonable basis during the relevant period [2]. Participation Information - Investors who suffered losses related to Snap Inc. are encouraged to participate in the ongoing securities fraud lawsuit, with a lead plaintiff deadline set for October 20, 2025 [2]. - Interested parties can contact the Law Offices of Frank R. Cruz for more information or to participate in the class action [3][4].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Sensus Healthcare, Inc. and its officers or directors [1]. Financial Performance - On August 7, 2025, Sensus reported a GAAP earnings-per-share of -$0.06 for Q2 2025, missing estimates by $0.09 [3]. - The company's revenue for the second quarter was $7.3 million, reflecting a year-over-year decline of 20.7% and missing estimates by $2 million [3]. - The revenue decline was primarily attributed to a lower number of units sold to a large customer, although there was some growth in recurring revenue from Fair Deal Agreements [3]. Stock Market Reaction - Following the financial results announcement, Sensus's stock price dropped by $1.89 per share, or 35.32%, closing at $3.46 per share on August 8, 2025 [4].

Core Viewpoint - A class action securities lawsuit has been filed against PubMatic, Inc. alleging securities fraud that negatively impacted investors between February 27, 2025, and August 11, 2025 [1][2]. Group 1: Lawsuit Details - The complaint claims that PubMatic's management made false statements and concealed critical information regarding a major demand side platform buyer shifting clients to a new platform, leading to reduced ad spend and revenue for PubMatic [2]. - The lawsuit asserts that the positive statements made by the defendants about PubMatic's business and prospects were materially misleading and lacked a reasonable basis due to the aforementioned issues [2]. Group 2: Next Steps for Investors - Investors who suffered losses in PubMatic, Inc. during the specified timeframe have until October 20, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, and there is no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the United States [4].

Core Viewpoint - A lawsuit has been filed against RxSight, Inc. and its senior executives for potential violations of federal securities laws, with claims related to undisclosed challenges in product adoption and a significant decline in stock value following revenue forecast cuts [1][2][4][5][6]. Group 1: Company Overview - RxSight, Inc. specializes in manufacturing light adjustable intraocular lenses for cataract surgery, with its primary product being the Light Adjustable Lens (LAL) that can be customized post-surgery through non-invasive light treatments [3]. Group 2: Legal Proceedings - The lawsuit is pending in the U.S. District Court for the Central District of California, titled Makaveev v. RxSight, Inc., et al., No. 25-cv-01596, with investors having until September 22, 2025, to seek lead plaintiff status [2]. Group 3: Financial Performance and Stock Impact - RxSight experienced a slowdown in LAL utilization, first noted in 2024, which was not disclosed to investors, leading to a significant stock price decline [4]. - On April 3, 2025, RxSight cut its 2025 full-year revenue forecast, resulting in a 38% drop in stock price from $26.12 to $16.21 per share [5]. - A further revenue forecast cut on July 8, 2025, attributed to slower LAL utilization and adoption challenges, caused another 38% decline in stock price from $12.79 to $7.95 per share [6].

Core Viewpoint - BellRing Brands, Inc. is under investigation for potential violations of federal securities laws, with concerns regarding the sustainability of its sales growth driven by temporary trade inventory loading rather than genuine consumer demand [1][2]. Group 1: Company Overview - BellRing Brands operates in the convenient nutrition category, primarily known for its brands Premier Protein and Dymatize, which offer ready-to-drink protein shakes and powders [2]. - The company reported that Premier Protein achieved an all-time high in household penetration, indicating strong demand and growth across all channels due to distribution expansion and promotional activities [2]. Group 2: Sales Growth Concerns - The sales growth during the relevant period may not be sustainable, as it could have been artificially inflated by temporary trade inventory loading at key retailers [2]. - On May 5, 2025, BellRing disclosed that several key retailers reduced their weeks of supply, which would negatively impact growth in Q3 2025 [3]. Group 3: Stock Performance - Following the May 5 announcement, BellRing's stock price dropped by $13.96, or over 18%, from $77.34 to $63.38 per share [3]. - On August 4, 2025, the company reported disappointing quarterly consumption of Premier Protein RTD Shakes, leading to a further decline in stock price by $17.46, or nearly 33%, from $53.64 to $36.18 per share [4].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of investors who purchased PubMatic, Inc. securities between February 27, 2025, and August 11, 2025, due to alleged misleading statements by the company [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that PubMatic made false and misleading statements regarding its business operations, particularly related to a significant demand side platform buyer shifting clients to a new platform, which negatively impacted PubMatic's ad spend and revenue [5]. - Investors who purchased PubMatic securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as Rosen Law Firm has achieved significant settlements in the past, including over $438 million for investors in 2019 [4]. - A lead plaintiff is needed to represent the class, and interested parties must move the Court by October 20, 2025, to serve in this capacity [3]. Group 3: Next Steps for Investors - To join the class action, investors can visit the provided link or contact Rosen Law Firm directly for more information [3][6]. - It is important to note that no class has been certified yet, and investors are not represented by counsel unless they retain one [7].

Core Viewpoint - A lawsuit has been filed against RxSight, Inc. and its senior executives for potential violations of federal securities laws, with claims related to undisclosed challenges in product adoption and a significant decline in stock value following revenue forecast cuts [1][2][4][5][6]. Group 1: Company Overview - RxSight, Inc. specializes in manufacturing light adjustable intraocular lenses for cataract surgery, with its primary product being the Light Adjustable Lens (LAL) that can be customized post-surgery through non-invasive light treatments [3]. Group 2: Legal Issues - The lawsuit claims violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, representing investors who purchased RxSight securities [2]. - The complaint highlights that RxSight failed to disclose "adoption challenges" and experienced a slowdown in LAL utilization, first noted in 2024 [4]. Group 3: Stock Performance - On April 3, 2025, RxSight cut its 2025 full-year revenue forecast, leading to a stock price drop of approximately 38%, from $26.12 to $16.21 per share [5]. - Following another revenue forecast cut on July 8, 2025, the stock price fell roughly 38% again, from $12.79 to $7.95 per share [6].

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of Semler Scientific, Inc. securities between March 10, 2021, and April 15, 2025, due to alleged misleading statements and undisclosed investigations by the DOJ [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that Semler Scientific failed to disclose a material investigation by the DOJ regarding violations of the False Claims Act, leading to materially false and misleading public statements [5]. - Investors who purchased Semler Scientific securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Participation Information - Interested parties can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. - A lead plaintiff must file a motion with the court by October 28, 2025, to represent other class members in the litigation [1][3]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including over $438 million for investors in 2019 [4]. - The firm has been recognized for its success in securities class action settlements, ranking No. 1 in 2017 and consistently in the top 4 since 2013 [4].